Resolution passed at the Annual General Meeting
Mar 27, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today held its Annual General Meeting, at which the Annual General Meeting.
Resolutions passed at the annual general meeting
Read moreOrphazyme to present at Cowen & Co Annual Health Care Conference
Mar 11, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Anders Hinsby, Chief Executive Officer at Orphazyme, will be presenting at the Cowen & Co Annual Health Care Conference in Boston, MA, USA on March 12, 2019.
Orphazyme to present at cowen co annual health care
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Mar 8, 2019
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in Orphazymes shares
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Mar 7, 2019
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in Orphazymes shares
Read moreNotice to convene Annual General Meeting
Mar 5, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the Orphazyme A/S Annual General Meeting will be held on ...
Notice to convene annual general meeting
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Mar 4, 2019
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme in connection with the vesting of Matching Shares.
Reporting of transactions in Orphazymes shares
Read moreOrphazyme announces Annual Report 2018
Mar 1, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced its Annual Report for 2018. Below is a summary from the report of Orphazyme’s business progress, financial performance for the year, and guidance for 2019. The full report is attached as a PDF file and can furthermore be found on the Company's website www.orphazyme.com.
Orphazyme announces annual report 2018
Read moreOrphazyme Annual Report 2018 Presentation
Feb 25, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the Company will be hosting an investor call at which Chief Executive Officer, Anders Hinsby, and Chief Financial Officer, Anders Vadsholt, will be presenting the Orphazyme Annual Report 2018. The presentation will be followed by a Q&A session.
Orphazyme annual report 2018 presentation
Read moreCapital increase of 26,060 shares (equivalent to approximately 0.13% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB
Jan 31, 2019
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today decided on a capital increase as a result of a directed issue of bonus shares to Kansas Life Sciences Development Company, Inc. (“KLSDC”) and UCL Business PLC (“UCLB”). The capital increase was decided pursuant to the Board of Directors’ authorization laid down in Article 3.6 of the Articles of Association.
Capital increase of 26 060 shares ...
Read moreMajor shareholder announcement
Jan 30, 2019
Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Novo Holdings A/S on behalf of Novo Nordisk Fonden that Novo Holdings A/S as of today’s date holds a total of 2,984,368 shares in the Company, corresponding to 14.97% of the share capital and the voting rights in the Company.
Major shareholder announcement
Read more